FDA conditionally approves first oral tablet to treat lymphoma in dogs

FDA granted conditional approval to verdinexor (Laverdia-CA1—Anivive Lifesciences) tablets for treating dogs with lymphoma. Verdinexor works to prevent certain proteins from leaving the nucleus of cancer cells, enabling these proteins to control the growth and prevent the spread of cancerous cells in dogs.

FDA granted conditional approval to verdinexor (Laverdia-CA1—Anivive Lifesciences) tablets for treating dogs with lymphoma. Verdinexor works to prevent certain proteins from leaving the nucleus of cancer cells, enabling these proteins to control the growth and prevent the spread of cancerous cells in dogs. When prescribed by a veterinarian, verdinexor can be administered to dogs at home by their owners. Verdinexor is given orally 2 times per week, with at least 72 hours between doses. The drug is the second treatment for lymphoma in dogs that FDA has conditionally approved. Tanovea-CA1, an injectable drug, received conditional approval in 2016. Steven M. Solomon, DVM, MPH, director of FDA's Center for Veterinary Medicine, said: "This conditional approval provides a much-needed option to treat dogs with lymphoma. We are encouraged to see drug companies bring forward applications for products to treat serious diseases, even if they affect relatively small populations." FDA's conditional approval lets veterinarians access treatments as drug companies continue to gather effectiveness data. Companies have up to 5 years to finalize their effectiveness studies to support a full approval for a drug.